Medical School: Suleyman Demirel University, 2004
Neurosurgery Training: Gazi University, Department of Neurosurgery, 2011
Dr Mehmet Tonge has international and nationwide 32 publications, 12 book chapters, 92 oral and poster presentations and 41 invited lectures, mostly on Stereotactic and Functional Neurosurgery.
2004-2011: Gazi University, Department of Neurosurgery (Residency)
2008: Zurich University Hospital, Department of Neurosurgery (Intraoperative MRI applications), Switzerland
2008: Zurich University Hospital, Department of Neurosurgery: Microneurosurgery, white matter dissection, interventional neuroradiology courses, Switzerland
2011 – 2012: Sinop Ataturk State Hospital, Neurosurgeon
2012 – 2013: Cankiri State Hospital, Neurosurgeon
2013 – 2014: Istanbul Medipol University, Department of Neurosurgery & Gamma Knife Center (Ass Prof)
2013 – now: Maastricht University Neurosurgery & Neuroscience Department (Visiting scientist, PhDc) The Netherlands
2014: Maastricht University, The Netherlands: Deep Brain Stimulation Fellowship 2014-2018: Istanbul Memorial Hospital Neurosurgery: Staff Neurosurgeon
2016-2018: Istanbul Florence Nightingale Hospital (Consultant, Gamma Knife Center)
2018-now: Istanbul Medipol University (Stereotactic & Functional Neurosurgery, Gamma Knife Center) Ass. Prof.)
Dr Mehmet Tonge has completed 4-year cycle EANS (European Association of Neurosurgical Societies) Training courses.
• Stereotactic & Functional Neurosurgery
• Surgery for movement disorders
• Gamma Knife Radiosurgery
* Surgery for pain & spasticity
* Psychosurgery
Research areas of interest:
* Deep brain stimulation
• Stereotactic radiosurgery
Read more
Medical School: Suleyman Demirel University, 2004
Neurosurgery Training: Gazi University, Department of Neurosurgery, 2011
Dr Mehmet Tonge has international and nationwide 32 publications, 12 book chapters, 92 oral and poster presentations and 41 invited lectures, mostly on Stereotactic and Functional Neurosurgery.
2004-2011: Gazi University, Department of Neurosurgery (Residency)
2008: Zurich University Hospital, Department of Neurosurgery (Intraoperative MRI applications), Switzerland
2008: Zurich University Hospital, Department of Neurosurgery: Microneurosurgery, white matter dissection, interventional neuroradiology courses, Switzerland
2011 – 2012: Sinop Ataturk State Hospital, Neurosurgeon
2012 – 2013: Cankiri State Hospital, Neurosurgeon
2013 – 2014: Istanbul Medipol University, Department of Neurosurgery & Gamma Knife Center (Ass Prof)
2013 – now: Maastricht University Neurosurgery & Neuroscience Department (Visiting scientist, PhDc) The Netherlands
2014: Maastricht University, The Netherlands: Deep Brain Stimulation Fellowship 2014-2018: Istanbul Memorial Hospital Neurosurgery: Staff Neurosurgeon
2016-2018: Istanbul Florence Nightingale Hospital (Consultant, Gamma Knife Center)
2018-now: Istanbul Medipol University (Stereotactic & Functional Neurosurgery, Gamma Knife Center) Ass. Prof.)
Dr Mehmet Tonge has completed 4-year cycle EANS (European Association of Neurosurgical Societies) Training courses.
• Stereotactic & Functional Neurosurgery
• Surgery for movement disorders
• Gamma Knife Radiosurgery
* Surgery for pain & spasticity
* Psychosurgery
Research areas of interest:
* Deep brain stimulation
• Stereotactic radiosurgery
Dr. Başak Bolluk Kılıç, MD graduated from Ankara University Faculty of Medicine in 2000 as a Medical Doctor. She completed her specialization training in the Department of Neurology at Ankara University in 2005.
In 2004, she worked as an observer at the Department of Movement Disorders at the University of Barcelona Medical Faculty. Having started her compulsory service in Kırşehir State Hospital in 2006, Dr. Başak Bolluk Kılıç, MD worked at Ankara Private Tandoğan Magnet Hospital in 2008, at Çamlıca Erdem Hospital between 2010-2016, at Bilgi University Electroneurophysiology Department between 2013-2017, at Bahçeşehir University Faculty of Medicine between 2017-2018 and at Medical Park between 2016-2018. She worked as an Assistant Professor at Göztepe Hospital.
In September 2018, at Istanbul Medipol University Parkinson's Disease and Movement Disorders Center (PARMER) she created the patients' treatment plans. She provides each patient with the most appropriate personalized medical follow-up and treatment support.
Read moreDr. Başak Bolluk Kılıç, MD graduated from Ankara University Faculty of Medicine in 2000 as a Medical Doctor. She completed her specialization training in the Department of Neurology at Ankara University in 2005.
In 2004, she worked as an observer at the Department of Movement Disorders at the University of Barcelona Medical Faculty. Having started her compulsory service in Kırşehir State Hospital in 2006, Dr. Başak Bolluk Kılıç, MD worked at Ankara Private Tandoğan Magnet Hospital in 2008, at Çamlıca Erdem Hospital between 2010-2016, at Bilgi University Electroneurophysiology Department between 2013-2017, at Bahçeşehir University Faculty of Medicine between 2017-2018 and at Medical Park between 2016-2018. She worked as an Assistant Professor at Göztepe Hospital.
In September 2018, at Istanbul Medipol University Parkinson's Disease and Movement Disorders Center (PARMER) she created the patients' treatment plans. She provides each patient with the most appropriate personalized medical follow-up and treatment support.
Experience
İSTİNYE UNIVERSITY FACULTY OF MEDICINE
Liv Hospital
Liv Hospital Ulus
Acıbadem Bodrum Hospital
Tatvan State Hospital
Tatvan State Hospital
CLEVELAND CLINIC
Dokuz Eylul University Faculty of Medicine
Education
DOKUZ EYLÜL UNIVERSITY FACULTY OF MEDICINE, FACULTY OF MEDICINE/DEPARTMENT OF SURGICAL MEDICAL SCIENCES/DEPARTMENT OF GENERAL SURGERY
Dokuz Eylül University, General Surgery
AKDENİZ UNIVERSITY, FACULTY OF MEDICINE
Title: The impact of sarcopenia on morbidity and long-term survival among patients with peritoneal metastases of colorectal origin treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a 10-year longitudinal analysis of a single-center experience.
Title: Randomized controlled trial of 8 weeks’ vs 12 weeks’ interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer.
Title: The effect of fibrin glue in preventing staple-line leak after sleeve gastrectomy: an experimental study in rats.
Title: Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy.
Title: Magnetic resonance-based pelvimetry and tumor volumetry can predict surgical difficulty and oncologic outcome in locally advanced mid–low rectal cancer.
Title: Is advanced age a hesitation for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer?
Title: Outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: A single-center experience.
Title: Predictive factors for conversion to open surgery in laparoscopic colorectal surgery.
Experience
İSTİNYE UNIVERSITY FACULTY OF MEDICINE
Liv Hospital
Liv Hospital Ulus
Acıbadem Bodrum Hospital
Tatvan State Hospital
Tatvan State Hospital
CLEVELAND CLINIC
Dokuz Eylul University Faculty of Medicine
Education
DOKUZ EYLÜL UNIVERSITY FACULTY OF MEDICINE, FACULTY OF MEDICINE/DEPARTMENT OF SURGICAL MEDICAL SCIENCES/DEPARTMENT OF GENERAL SURGERY
Dokuz Eylül University, General Surgery
AKDENİZ UNIVERSITY, FACULTY OF MEDICINE
Title: The impact of sarcopenia on morbidity and long-term survival among patients with peritoneal metastases of colorectal origin treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a 10-year longitudinal analysis of a single-center experience.
Title: Randomized controlled trial of 8 weeks’ vs 12 weeks’ interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer.
Title: The effect of fibrin glue in preventing staple-line leak after sleeve gastrectomy: an experimental study in rats.
Title: Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy.
Title: Magnetic resonance-based pelvimetry and tumor volumetry can predict surgical difficulty and oncologic outcome in locally advanced mid–low rectal cancer.
Title: Is advanced age a hesitation for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer?
Title: Outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: A single-center experience.
Title: Predictive factors for conversion to open surgery in laparoscopic colorectal surgery.
Doctor's visit | price on request |
Liposuction | $5000 |
Myomectomy (removal of uterine fibroids) | $4000 - $5000 |
Discectomy | $3000 - $4000 |
Specializations
Brain Tumors
Aneurysm Surgery
Pituitary Surgery
Spine Surgery
Waist neck and back hernias
Spine Tumors
Spinal Fractures
Peripheral Nerve Surgery
Read more
Specializations
Brain Tumors
Aneurysm Surgery
Pituitary Surgery
Spine Surgery
Waist neck and back hernias
Spine Tumors
Spinal Fractures
Peripheral Nerve Surgery
PROFESSIONAL EXPERIENCE
2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine
2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine
06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine
10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship
2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship
2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist
2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.
EDUCATION
2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey
2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey
2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey
2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey
2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.
2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey
INTERNATIONAL CLINICAL TRIALS:
1. Astefania - ROCHE
2. PFİZER
3. RECITE - AMGEN
4. NAVIGATE - BAYER
5. RUBY - Tesaro (PRA)
6. ENGOT-ov43/GOG-3036 - MSD
7. ASTRA ZENECA
8. ROSY-O - ASTRA ZENECA
INTERNATIONAL PUBLICATIONS
I. Published journal articles indexed by SCI, SSCI, and AHCI
Weekly Paclitaxel in Classic Kaposi Sarcoma
Carboplatin Desensitization in Ovarian Carcinoma
High-Dose Chemotherapy for Ewing’s Sarcoma
Multidrug Refractory TFE3(+) Renal Cell Carcinoma
Crizotinib Efficacy in NSCLC with MET Alterations
Clinicopathological Features in ALK Mutant NSCLC
PSMA-Based Tumor Burden in Prostate Cancer
Atezolizumab in Metastatic Urothelial Carcinoma
Pulmonary Sarcomatoid Carcinoma
Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma
Atezolizumab with Chemotherapy in Small Cell Lung Cancer
FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer
Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients
Real-Life Efficacy of Osimertinib in Advanced NSCLC
ALK-Positive Cells Percentage and Alectinib Efficacy
Real-World Data on Alectinib in ALK-Positive NSCLC
Prognostic Factors in Metastatic RCC with T790M Mutation
FLOT Regimen in Metastatic Gastric Cancer
Desensitization Protocol in Lenalidomide Hypersensitivity Reactions
Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity
Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors
Subsequent Treatments in Hormone-Positive Breast Cancer Progression
Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer
Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer
Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer
Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer
Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients
Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients
Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases
FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer
Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer
Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma
Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma
Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)
Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)
Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.
Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49
Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4
Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.
Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology
Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)
Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)
Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)
Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)
Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye
Thesis:
Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)
International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)
Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination
Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study
Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer
Efficacy of temozolomide in pretreated patients with metastatic sarcoma
Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors
Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma
Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases
Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma
Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
Read more
PROFESSIONAL EXPERIENCE
2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine
2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine
06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine
10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship
2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship
2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist
2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.
EDUCATION
2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey
2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey
2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey
2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey
2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.
2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey
INTERNATIONAL CLINICAL TRIALS:
1. Astefania - ROCHE
2. PFİZER
3. RECITE - AMGEN
4. NAVIGATE - BAYER
5. RUBY - Tesaro (PRA)
6. ENGOT-ov43/GOG-3036 - MSD
7. ASTRA ZENECA
8. ROSY-O - ASTRA ZENECA
INTERNATIONAL PUBLICATIONS
I. Published journal articles indexed by SCI, SSCI, and AHCI
Weekly Paclitaxel in Classic Kaposi Sarcoma
Carboplatin Desensitization in Ovarian Carcinoma
High-Dose Chemotherapy for Ewing’s Sarcoma
Multidrug Refractory TFE3(+) Renal Cell Carcinoma
Crizotinib Efficacy in NSCLC with MET Alterations
Clinicopathological Features in ALK Mutant NSCLC
PSMA-Based Tumor Burden in Prostate Cancer
Atezolizumab in Metastatic Urothelial Carcinoma
Pulmonary Sarcomatoid Carcinoma
Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma
Atezolizumab with Chemotherapy in Small Cell Lung Cancer
FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer
Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients
Real-Life Efficacy of Osimertinib in Advanced NSCLC
ALK-Positive Cells Percentage and Alectinib Efficacy
Real-World Data on Alectinib in ALK-Positive NSCLC
Prognostic Factors in Metastatic RCC with T790M Mutation
FLOT Regimen in Metastatic Gastric Cancer
Desensitization Protocol in Lenalidomide Hypersensitivity Reactions
Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity
Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors
Subsequent Treatments in Hormone-Positive Breast Cancer Progression
Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer
Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer
Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer
Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer
Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients
Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients
Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases
FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer
Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer
Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma
Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma
Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)
Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)
Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.
Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49
Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4
Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.
Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology
Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)
Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)
Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)
Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)
Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye
Thesis:
Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)
International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)
Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination
Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study
Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer
Efficacy of temozolomide in pretreated patients with metastatic sarcoma
Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors
Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma
Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases
Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma
Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
Doctor's visit | price on request |
Liposuction | $5000 |
Myomectomy (removal of uterine fibroids) | $4000 - $5000 |
Discectomy | $3000 - $4000 |
Medical Specialization
Hacettepe University 2017 - 2007
Medical Specialization (Minor)
Ufuk University 2011 - 2009
Doctorate
Ankara University 2021 - 2000
Undergraduate
Ankara University 2006
Research Assistant
Biotechnology Department, Biotechnology Institute, Ankara University
September 01, 2009 - October 08, 2021
Research Assistant
Department of Pediatrics, Faculty of Medicine, Hacettepe University
February 27, 2014 - February 28, 2017
Research Assistant
Dr. Ridvan Ege Health Research and Application Center, Ufuk University
November 27, 2007 - December 09, 2011
Read more
Medical Specialization
Hacettepe University 2017 - 2007
Medical Specialization (Minor)
Ufuk University 2011 - 2009
Doctorate
Ankara University 2021 - 2000
Undergraduate
Ankara University 2006
Research Assistant
Biotechnology Department, Biotechnology Institute, Ankara University
September 01, 2009 - October 08, 2021
Research Assistant
Department of Pediatrics, Faculty of Medicine, Hacettepe University
February 27, 2014 - February 28, 2017
Research Assistant
Dr. Ridvan Ege Health Research and Application Center, Ufuk University
November 27, 2007 - December 09, 2011
Education
Career
Education
Career
Balgrist University, Zurich
Bezmialem Vakif University
Istanbul Sisli Etfal Research and Training Hospital
Hospital for Special Surgery, USA
Istanbul University, Istanbul Faculty of Medicine
Istanbul Sisli Hamidiye Etfal Research and Training Hospital
Kilis State Hospital
Yedikule Surp Pırgiç Armenian Hospital
Istanbul Sisli Hamidiye Etfal Research and Training Hospital
Medipol Acıbadem Hospital
Balgrist University, Zurich
Bezmialem Vakif University
Istanbul Sisli Etfal Research and Training Hospital
Hospital for Special Surgery, USA
Istanbul University, Istanbul Faculty of Medicine
Istanbul Sisli Hamidiye Etfal Research and Training Hospital
Kilis State Hospital
Yedikule Surp Pırgiç Armenian Hospital
Istanbul Sisli Hamidiye Etfal Research and Training Hospital
Medipol Acıbadem Hospital
Education
Experience
Education
Experience
Prof. Dr. Gülşah Bademci is a physician specialized in the field of brain, nerve, spine, and spinal cord surgery. She graduated as the fourth-ranked student from Ankara University Faculty of Medicine in 1993. She obtained her title as a brain and nerve surgeon from the Ankara University Faculty of Medicine Department of Brain and Nerve Surgery in 2001. In 2008, she became an associate professor at the Kırıkkale University Faculty of Medicine, and in 2021, she became a professor at the Yüksek İhtisas University Faculty of Medicine. She has contributed to numerous international publications, serving as a research and clinical fellow at the University of Arkansas Medical Sciences with Prof. Dr. M. Gazi Yaşargil, and as a research fellow at Yale University School of Medicine. She holds ECFMG America Board Step 1 and EANS European Board certificates. She speaks advanced-level English and has awards in tennis and swimming. She also pursues professional-level caricature art and medical illustration. In her 30-year career, she has performed numerous surgeries as a brain and nerve surgery specialist, particularly in spinal canal stenosis surgery, lumbar and cervical disc herniations, brain tumors, hydrocephalus surgery, and nerve compressions.
Read moreProf. Dr. Gülşah Bademci is a physician specialized in the field of brain, nerve, spine, and spinal cord surgery. She graduated as the fourth-ranked student from Ankara University Faculty of Medicine in 1993. She obtained her title as a brain and nerve surgeon from the Ankara University Faculty of Medicine Department of Brain and Nerve Surgery in 2001. In 2008, she became an associate professor at the Kırıkkale University Faculty of Medicine, and in 2021, she became a professor at the Yüksek İhtisas University Faculty of Medicine. She has contributed to numerous international publications, serving as a research and clinical fellow at the University of Arkansas Medical Sciences with Prof. Dr. M. Gazi Yaşargil, and as a research fellow at Yale University School of Medicine. She holds ECFMG America Board Step 1 and EANS European Board certificates. She speaks advanced-level English and has awards in tennis and swimming. She also pursues professional-level caricature art and medical illustration. In her 30-year career, she has performed numerous surgeries as a brain and nerve surgery specialist, particularly in spinal canal stenosis surgery, lumbar and cervical disc herniations, brain tumors, hydrocephalus surgery, and nerve compressions.
Prof. M.D. Yusuf Serdar Sakin was born in Nevşehir in 1978. After completing his primary and secondary education in Ankara, he graduated from the Faculty of Medicine at Gülhane Military Medical Academy in 2002.
Following his graduation, he served in Gole/Ardahan for two years. He started his internal medicine training at the Department of Internal Medicine, Gülhane Faculty of Medicine.
After completing his training, he worked as an internal medicine specialist in Ankara. A year later, he began additional training in the Department of Gastroenterology at Gülhane Faculty of Medicine and completed his training in 2014.
After graduation, Yusuf Serdar Sakin continued to work in the same department. He also received advanced endoscopy and Motility training at AMC Center in the Netherlands in 2017.
After obtaining the title of Associate Professor in 2017, he became a Professor in 2023.
He currently provides medical services to patients at Koru Ankara Hospital. His areas of medical interest include:
-Endoscopic retrograde cholangiopancreatography (ERCP)
-Push enteroscopy
-Endoscopic mucosal resection
-High-resolution manometry
-pH/pH-impedance metry analysis
-Advanced endoscopic procedures (stenting, dilation, etc.)
-Gastrointestinal motility disorders
-Gastroesophageal reflux disease
-Inflammatory bowel diseases
-Advanced endoscopic procedures and pancreatitis.
Prof. M.D. Yusuf Serdar Sakin was born in Nevşehir in 1978. After completing his primary and secondary education in Ankara, he graduated from the Faculty of Medicine at Gülhane Military Medical Academy in 2002.
Following his graduation, he served in Gole/Ardahan for two years. He started his internal medicine training at the Department of Internal Medicine, Gülhane Faculty of Medicine.
After completing his training, he worked as an internal medicine specialist in Ankara. A year later, he began additional training in the Department of Gastroenterology at Gülhane Faculty of Medicine and completed his training in 2014.
After graduation, Yusuf Serdar Sakin continued to work in the same department. He also received advanced endoscopy and Motility training at AMC Center in the Netherlands in 2017.
After obtaining the title of Associate Professor in 2017, he became a Professor in 2023.
He currently provides medical services to patients at Koru Ankara Hospital. His areas of medical interest include:
-Endoscopic retrograde cholangiopancreatography (ERCP)
-Push enteroscopy
-Endoscopic mucosal resection
-High-resolution manometry
-pH/pH-impedance metry analysis
-Advanced endoscopic procedures (stenting, dilation, etc.)
-Gastrointestinal motility disorders
-Gastroesophageal reflux disease
-Inflammatory bowel diseases
-Advanced endoscopic procedures and pancreatitis.
Prof. Dr. Osman İLHAN graduated from Ankara University Faculty of Medicine in 1978. After completing his internal medicine residency at the same faculty in 1982, he served as a senior resident at the GATA Hematology Clinic during his military service. After completing his mandatory service at SSK Ulus Hospital, he returned to Ankara University Faculty of Medicine for a subspecialty. In 1990, he became an associate professor of hematology. He worked in Genoa, Italy to increase his knowledge and experience in leukemia. He was part of the team that performed the first bone marrow stem cell transplant in Turkey. In 1996, he went to the MD Anderson Cancer Center in the USA to work on "Stem Cell Mobilization, Cryopreservation, and Transplantation." In 1996, he became a professor of hematology. In 1999, he was elected as the regional president of ESFH (European Society for Hemapheresis). Dr. İlhan, who was the founder and president of the Hemapheresis Society in 2000, joined the World Apheresis Association (WAA) in 2001. He became the President of the Turkish Hematology Association in October 2001. Dr. İlhan, who is an active member of the European Hematology Association (EHA), was a member of the accreditation committee (ECAH) for education. He played a role in the accreditation of Turkish hematologists in CME credits by participating in the accreditation of congresses and courses held in Turkey as a Provider Status. He served as the founding president of the Cellular Therapy and Regenerative Medicine Association established in 2008. He became the founding president of the Geriatric Hematology Association in 2011. He is the Honorary President of the World Apheresis Congress (WAA) held in 2012. Dr. İlhan, who previously served on drug licensing and ethics committees at the Ministry of Health, has also served as the Chairman of the Photopheresis-Apheresis Commission and the Scientific Committee for Bone Marrow Transplantation, as well as the Chairman of the National Organ Tissue Cell Coordination Board, the Scientific Board of Cord Blood, and the Stem Cell Research Board. He is the founding president of the STEM CELL FOUNDATION and has played an important role in the establishment of TURKOK (Turkish Stem Cell Donor Bank). Dr. İlhan has over 300 publications in journals registered in PubMed and more than 5000 citations. He holds the Platinum CME certificate from the European Hematology Association. He owns four brands/patents named “Kökten Çözüm (Deep Solution), Telehematoloji (Telehematology), Hemaferez (Hemapheresis), Kanser Kök Hücresi (Cancer Stem Cell)”. He is currently the President of the Ankara Medical Association. Prof. Dr. Osman İlhan, who served at Ankara University Faculty of Medicine for 50 years, began working at Özel Koru Ankara Hospital as of January 1, 2023.
His medical interests include:
Hematopoietic Stem Cell Transplantation (Autologous, Allogeneic)
Acute Leukemia
Chronic Leukemia Treatments
Hodgkin Lymphoma
Non-Hodgkin Lymphoma Treatments
Multiple Myeloma Treatments, MDS
Aplastic Anemia
ITP
TTP Treatments
Hypercoagulability
Hereditary Thrombophilia Treatments
Therapeutic Apheresis
Photopheresis
Geriatric Hematology Diseases.
Read moreProf. Dr. Osman İLHAN graduated from Ankara University Faculty of Medicine in 1978. After completing his internal medicine residency at the same faculty in 1982, he served as a senior resident at the GATA Hematology Clinic during his military service. After completing his mandatory service at SSK Ulus Hospital, he returned to Ankara University Faculty of Medicine for a subspecialty. In 1990, he became an associate professor of hematology. He worked in Genoa, Italy to increase his knowledge and experience in leukemia. He was part of the team that performed the first bone marrow stem cell transplant in Turkey. In 1996, he went to the MD Anderson Cancer Center in the USA to work on "Stem Cell Mobilization, Cryopreservation, and Transplantation." In 1996, he became a professor of hematology. In 1999, he was elected as the regional president of ESFH (European Society for Hemapheresis). Dr. İlhan, who was the founder and president of the Hemapheresis Society in 2000, joined the World Apheresis Association (WAA) in 2001. He became the President of the Turkish Hematology Association in October 2001. Dr. İlhan, who is an active member of the European Hematology Association (EHA), was a member of the accreditation committee (ECAH) for education. He played a role in the accreditation of Turkish hematologists in CME credits by participating in the accreditation of congresses and courses held in Turkey as a Provider Status. He served as the founding president of the Cellular Therapy and Regenerative Medicine Association established in 2008. He became the founding president of the Geriatric Hematology Association in 2011. He is the Honorary President of the World Apheresis Congress (WAA) held in 2012. Dr. İlhan, who previously served on drug licensing and ethics committees at the Ministry of Health, has also served as the Chairman of the Photopheresis-Apheresis Commission and the Scientific Committee for Bone Marrow Transplantation, as well as the Chairman of the National Organ Tissue Cell Coordination Board, the Scientific Board of Cord Blood, and the Stem Cell Research Board. He is the founding president of the STEM CELL FOUNDATION and has played an important role in the establishment of TURKOK (Turkish Stem Cell Donor Bank). Dr. İlhan has over 300 publications in journals registered in PubMed and more than 5000 citations. He holds the Platinum CME certificate from the European Hematology Association. He owns four brands/patents named “Kökten Çözüm (Deep Solution), Telehematoloji (Telehematology), Hemaferez (Hemapheresis), Kanser Kök Hücresi (Cancer Stem Cell)”. He is currently the President of the Ankara Medical Association. Prof. Dr. Osman İlhan, who served at Ankara University Faculty of Medicine for 50 years, began working at Özel Koru Ankara Hospital as of January 1, 2023.
His medical interests include:
Hematopoietic Stem Cell Transplantation (Autologous, Allogeneic)
Acute Leukemia
Chronic Leukemia Treatments
Hodgkin Lymphoma
Non-Hodgkin Lymphoma Treatments
Multiple Myeloma Treatments, MDS
Aplastic Anemia
ITP
TTP Treatments
Hypercoagulability
Hereditary Thrombophilia Treatments
Therapeutic Apheresis
Photopheresis
Geriatric Hematology Diseases.
Prof. Dr. Süleyman Bülent Bektaşer was born in Kayseri in 1968. He graduated from Hacettepe University Faculty of Medicine in 1992. In 1997, he completed his specialization training in Orthopedics and Traumatology at Ankara Dr. Muhittin Ülker Emergency and Traumatology Hospital with a thesis on "Total Knee Arthroplasty Applications and Early Results". Between 1997 and 2000, he worked as a specialist doctor at the Orthopedics and Traumatology Clinic of the same hospital, and between 2000 and 2004, he served as a chief resident at the same hospital. Between 2004 and 2013, he worked as a chief resident in the Orthopedics and Traumatology Clinic at Ankara Atatürk Training and Research Hospital of the Ministry of Health. He became an associate professor in 2004 and worked as a lecturer at Ankara Atatürk Training and Research Hospital between 2014 and 2016. He was appointed as a full professor at Yüksek İhtisas University in 2018. Throughout his academic career, he has published numerous scientific articles. He currently works at Koru Ankara Hospital and his medical interests include:
Hip, knee, shoulder arthroplasty (prosthetic surgery, robotic knee prosthesis surgery)
Extremity traumas (fractures and muscle/tendon tears)
Orthopedic oncology surgeries
Sports injuries and arthroscopy
Hand surgery
Shoulder and elbow surgery.
Read moreProf. Dr. Süleyman Bülent Bektaşer was born in Kayseri in 1968. He graduated from Hacettepe University Faculty of Medicine in 1992. In 1997, he completed his specialization training in Orthopedics and Traumatology at Ankara Dr. Muhittin Ülker Emergency and Traumatology Hospital with a thesis on "Total Knee Arthroplasty Applications and Early Results". Between 1997 and 2000, he worked as a specialist doctor at the Orthopedics and Traumatology Clinic of the same hospital, and between 2000 and 2004, he served as a chief resident at the same hospital. Between 2004 and 2013, he worked as a chief resident in the Orthopedics and Traumatology Clinic at Ankara Atatürk Training and Research Hospital of the Ministry of Health. He became an associate professor in 2004 and worked as a lecturer at Ankara Atatürk Training and Research Hospital between 2014 and 2016. He was appointed as a full professor at Yüksek İhtisas University in 2018. Throughout his academic career, he has published numerous scientific articles. He currently works at Koru Ankara Hospital and his medical interests include:
Hip, knee, shoulder arthroplasty (prosthetic surgery, robotic knee prosthesis surgery)
Extremity traumas (fractures and muscle/tendon tears)
Orthopedic oncology surgeries
Sports injuries and arthroscopy
Hand surgery
Shoulder and elbow surgery.
Kürşat Fidancı is a medical doctor who graduated from GATA Faculty of Medicine in 1999. Between 2000 and 2002, he served as the Chief Physician of the Şırnak Çakırsöğüt Commando Brigade. He completed his residency in Pediatrics from 2002 to 2006 at Istanbul GATA Haydarpaşa Training and Research Hospital. He worked as a Pediatrician at Ankara Beytepe Military Hospital between 2006 and 2009. He completed his subspecialty training in Paediatric Cardiology at GATA Faculty of Medicine Pediatric Cardiology Department from 2010 to 2013. He became an Assistant Professor in 2014 and obtained the title of Associate Professor in April 2016. He worked as a faculty member in the Department of Pediatric Cardiology at GATA Faculty of Medicine between September 2014 and December 2021. As a pediatric cardiologist, Dr. Kürşat Fidancı has seen numerous patients and his medical interests include Fetal Echocardiography, Congenital Heart Diseases, Rheumatic Heart Diseases, Rhythm Disorders, and Athlete's Heart Health and Follow-up.
Read moreKürşat Fidancı is a medical doctor who graduated from GATA Faculty of Medicine in 1999. Between 2000 and 2002, he served as the Chief Physician of the Şırnak Çakırsöğüt Commando Brigade. He completed his residency in Pediatrics from 2002 to 2006 at Istanbul GATA Haydarpaşa Training and Research Hospital. He worked as a Pediatrician at Ankara Beytepe Military Hospital between 2006 and 2009. He completed his subspecialty training in Paediatric Cardiology at GATA Faculty of Medicine Pediatric Cardiology Department from 2010 to 2013. He became an Assistant Professor in 2014 and obtained the title of Associate Professor in April 2016. He worked as a faculty member in the Department of Pediatric Cardiology at GATA Faculty of Medicine between September 2014 and December 2021. As a pediatric cardiologist, Dr. Kürşat Fidancı has seen numerous patients and his medical interests include Fetal Echocardiography, Congenital Heart Diseases, Rheumatic Heart Diseases, Rhythm Disorders, and Athlete's Heart Health and Follow-up.
Sema Yılmaz was born on July 30, 1965. She received her undergraduate degree from Istanbul University Cerrahpaşa Medical Faculty and completed her medical residency training at the Department of Pediatrics at Zeynep Kamil Women's and Children's Health and Diseases Hospital. She also completed her medical subspecialty training in Pediatric Hematology/Oncology at Cukurova University. Her medical residency thesis was titled "The Relationship Between Morning First Urine Density and Nocturnal Enuresis in Children Aged 3-6 Years", and her medical subspecialty thesis was titled "Comparison of Sphingosine 1-phosphate Receptor 4 Gene Expression in Healthy Children and Neuroblastoma Patients". She started her medical career as a general practitioner. After working as a general practitioner for 4 years, she worked as a doctor researcher at Zeynep Kamil Women's and Children's Health and Diseases Training and Research Hospital for 5 years. She then served as a specialist doctor, assistant professor, and associate professor at various institutions. She worked at Houston MD Anderson, North Carolina-UNC, Boston-Harvard University in the USA. Additionally, she conducted research on cell therapies. She received the title of professor in Pediatric Hematology/Oncology at Usak Medical Faculty. She is a member of the Turkish Pediatric Oncology Group, European Association for Cancer Research (EACR), Turkish Medical Association, Turkish National Pediatrics Association, Turkish Pediatrics Association, Pediatrics Specialty Academy Association (PUADER), Turkish Immunology Association, Turkish Hematology Association, and Molecular Oncology Association (MOKAD). She currently serves her patients at Koru Hospital. Her medical interests include:
Cell therapies in childhood cancers
Cancer immunology
Investigation of genetic pathways responsible for cancer and metastasis
Pulmonary microbiota
BAL transplantation
Read moreSema Yılmaz was born on July 30, 1965. She received her undergraduate degree from Istanbul University Cerrahpaşa Medical Faculty and completed her medical residency training at the Department of Pediatrics at Zeynep Kamil Women's and Children's Health and Diseases Hospital. She also completed her medical subspecialty training in Pediatric Hematology/Oncology at Cukurova University. Her medical residency thesis was titled "The Relationship Between Morning First Urine Density and Nocturnal Enuresis in Children Aged 3-6 Years", and her medical subspecialty thesis was titled "Comparison of Sphingosine 1-phosphate Receptor 4 Gene Expression in Healthy Children and Neuroblastoma Patients". She started her medical career as a general practitioner. After working as a general practitioner for 4 years, she worked as a doctor researcher at Zeynep Kamil Women's and Children's Health and Diseases Training and Research Hospital for 5 years. She then served as a specialist doctor, assistant professor, and associate professor at various institutions. She worked at Houston MD Anderson, North Carolina-UNC, Boston-Harvard University in the USA. Additionally, she conducted research on cell therapies. She received the title of professor in Pediatric Hematology/Oncology at Usak Medical Faculty. She is a member of the Turkish Pediatric Oncology Group, European Association for Cancer Research (EACR), Turkish Medical Association, Turkish National Pediatrics Association, Turkish Pediatrics Association, Pediatrics Specialty Academy Association (PUADER), Turkish Immunology Association, Turkish Hematology Association, and Molecular Oncology Association (MOKAD). She currently serves her patients at Koru Hospital. Her medical interests include:
Cell therapies in childhood cancers
Cancer immunology
Investigation of genetic pathways responsible for cancer and metastasis
Pulmonary microbiota
BAL transplantation